Soleno Therapeutics Investors Urged to Act: Class Action Deadlines Approaching

In a significant development for shareholders of Soleno Therapeutics, ClaimsFiler, a dedicated service for shareholders, has issued an urgent reminder. Investors who suffered losses exceeding $100,000 during a specific period must act quickly if they wish to participate as lead plaintiffs in a pending class action lawsuit against the company. The deadline for filing these applications is set for May 5, 2026, and shareholders are encouraged not to miss this critical opportunity.

Background of the Lawsuit

The class action suit pertains to allegations against Soleno Therapeutics, Inc. (NasdaqCM: SLNO) and certain executives for failing to disclose crucial information during the class period, which spans from March 26, 2025, to November 4, 2025. Investors who acquired shares during this timeframe are particularly affected by the claims of misinformation and potential safety concerns regarding Soleno's only commercial product, DCCR. This medication is aimed at treating hyperphagia in individuals with Prader-Willi syndrome (PWS).

The allegations state that during the aforementioned class period, Soleno and its executives were believed to have understated and mischaracterized key safety issues associated with DCCR. It is asserted that the Phase 3 clinical trial for this product did not adequately reveal significant risks, including excessive fluid retention observed in clinical participants, despite these being crucial to understanding the product's safety.

The consequences of these omissions, as per the lawsuit, include potential severe adverse effects that could arise post-commercial launch. These effects jeopardize the medication's commercial viability, reflecting risks such as patient drop-out rates, hesitance from prescribers, and adverse regulatory action which may lead to legal ramifications and reputational damage.

Understanding ClaimsFiler's Role

ClaimsFiler acts as a pivotal resource for average retail investors, ensuring they possess the vital information needed to recover their investments from significant securities class action settlements. Their platform allows investors to register for free access to updates and information regarding various class actions, including filing instructions and deadlines. Additionally, ClaimsFiler enables users to upload portfolio transactional data and receive notifications about relevant legal cases, providing necessary guidance and legal options.

For Soleno investors who wish to understand their rights and explore participation in the class action, further details can be sought via the ClaimsFiler website or by reaching out through their help line.

Legal Guidance Available

Lawyers from Kahn Swick & Foti, LLC are readily accessible for discussions regarding the case, enabling investors to understand the implications and next steps to take. Soleno shareholders should take advantage of this service, especially as the deadline looms ever closer.

In summary, as the class action deadline approaches, impacted investors are strongly advised to act swiftly and efficiently to ensure their voices are heard and their losses potentially compensated. The securities class action against Soleno Therapeutics represents a crucial moment for many shareholders navigating through the consequences of uninformed investment choices that stemmed from the company's alleged misrepresentations.

For further assistance and inquiries about the litigation process, investors can visit ClaimsFiler's website or contact the helpline at (844) 367-9658.